Abstract
To drive high-quality omics translational research using The Cancer Genome Atlas (TCGA) data, a TCGA Pan-Cancer Clinical Data Resource was proposed. However, there is an out-of-step issue between clinical outcomes and the omics data of TCGA for skin cutaneous melanoma (SKCM), due to the majority of metastatic samples. In clinical cases, the survival time started from the initial SKCM diagnosis, while the omics data were characterized at TCGA sampling. This study aimed to address this issue by proposing an observed survival interval (OBS), which was defined as the time interval from TCGA sampling to patient death or last follow-up. We compared the OBS with the usual recommended overall survival (OS) by associating them with both clinical data and microRNA sequencing data of TCGA-SKCM. We found that the OS of primary SKCM was significantly shorter than that of metastatic SKCM, while the opposite happened if OBS was compared. OS was associated with the pathological stage of both primary and metastatic SKCM, while OBS was associated with the pathological stage of primary SKCM but not that of metastatic SKCM. Five previously cross-validated survival-associated microRNAs were found to be associated with the OBS rather than OS in meta...Continue Reading
References
Feb 4, 2010·Cancer Research·Xiaoxia HuXiaowei Wang
Feb 25, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Miguel F SeguraEva Hernando
Apr 2, 2010·The Journal of Investigative Dermatology·Stefano CaramutaWeng-Onn Lui
Jan 10, 2012·British Journal of Cancer·Y XuD W Melton
Aug 21, 2013·Bioinformatics·Sarah E ReeseJeanette E Eckel-Passow
Sep 13, 2013·Statistics in Medicine·Paul BlancheHélène Jacqmin-Gadda
Dec 11, 2014·Pigment Cell & Melanoma Research·Varsha TembeGraham J Mann
Dec 18, 2014·Genome Biology·Michael I LoveSimon Anders
Jun 20, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Doug HannifordEva Hernando
Jun 20, 2015·Cell·UNKNOWN Cancer Genome Atlas Network
Sep 1, 2013·EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [et Al.]·Z AliJ Larkin
Jan 15, 2016·The Journal of Investigative Dermatology·Kaushala JayawardanaJean Yang
May 5, 2016·Genomics·Yu JiangShuangge Ma
Oct 14, 2016·Lancet·UNKNOWN GBD 2015 Mortality and Causes of Death Collaborators
Dec 14, 2016·Journal of Dermatological Science·Xijia ChenLiucun Zhu
Oct 14, 2017·CA: a Cancer Journal for Clinicians·Jeffrey E GershenwaldUNKNOWN for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Disc
Nov 5, 2017·Oncotarget·Xu MaGuofeng Liu
Jan 10, 2018·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Feb 14, 2018·International Journal of Oncology·Shuocheng YangXuan Zeng
Apr 7, 2018·Cell·Jianfang LiuHai Hu
Jan 22, 2019·Frontiers in Genetics·Jie XiongLe Guo
Citations
Sep 14, 2019·Cancer Cell International·Liwei WangZhiwen Chen
Feb 7, 2020·Journal of Translational Medicine·Natasha A N JorgeMariana Boroni
Jan 10, 2020·PeerJ·Jie XiongBihai Zhao
Apr 17, 2020·Frontiers in Bioengineering and Biotechnology·Yang ShengLiang Geyu
Oct 28, 2019·Cancers·Chad Brenner
Nov 17, 2020·Frontiers in Immunology·Ya-Nan XueWei-Qiang Tan
Jan 19, 2021·Oncoimmunology·Connie C QiuAna M Gamero
Mar 6, 2021·Frontiers in Molecular Biosciences·Zhengtong LvYuan Li
May 6, 2021·Oncogene·Ola BillingOskar Hemmingsson
Oct 12, 2021·Frontiers in Molecular Biosciences·Ayşegül Kutlay, Yeşim Aydin Son